Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms anti-CD3/anti-Claudin18.2 bispecific T-cell engager(Mabworks Biotech) |
Target |
Action stimulants, inhibitors |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), CLDN18.2 inhibitors(Claudin 18.2 inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic Cancer | Preclinical | China | 24 Mar 2022 | |
Stomach Cancer | Preclinical | China | 24 Mar 2022 |